<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang xml:lang>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Your Digest for Sunday, Feb 04, 2024 08:59 PM</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
  </style>
  <style type="text/css">
:root,
::backdrop {

--sans-font: -apple-system, BlinkMacSystemFont, "Avenir Next", Avenir,
"Nimbus Sans L", Roboto, "Noto Sans", "Segoe UI", Arial, Helvetica,
"Helvetica Neue", sans-serif;
--mono-font: Consolas, Menlo, Monaco, "Andale Mono", "Ubuntu Mono", monospace;
--standard-border-radius: 5px;

--bg: #fff;
--accent-bg: #f5f7ff;
--text: #212121;
--text-light: #585858;
--border: #898EA4;
--accent: #0d47a1;
--code: #d81b60;
--preformatted: #444;
--marked: #ffdd33;
--disabled: #efefef;
}

@media (prefers-color-scheme: dark) {
:root,
::backdrop {
color-scheme: dark;
--bg: #212121;
--accent-bg: #2b2b2b;
--text: #dcdcdc;
--text-light: #ababab;
--accent: #ffb300;
--code: #f06292;
--preformatted: #ccc;
--disabled: #111;
}

img,
video {
opacity: 0.8;
}
}

*, *::before, *::after {
box-sizing: border-box;
}

textarea,
select,
input,
progress {
appearance: none;
-webkit-appearance: none;
-moz-appearance: none;
}
html {

font-family: var(--sans-font);
scroll-behavior: smooth;
}

body {
color: var(--text);
background-color: var(--bg);
font-size: 1.15rem;
line-height: 1.5;
display: grid;
grid-template-columns: 1fr min(45rem, 90%) 1fr;
margin: 0;
}
body > * {
grid-column: 2;
}

body > header {
background-color: var(--accent-bg);
border-bottom: 1px solid var(--border);
text-align: center;
padding: 0 0.5rem 2rem 0.5rem;
grid-column: 1 / -1;
}
body > header h1 {
max-width: 1200px;
margin: 1rem auto;
}
body > header p {
max-width: 40rem;
margin: 1rem auto;
}

main {
padding-top: 1.5rem;
}
body > footer {
margin-top: 4rem;
padding: 2rem 1rem 1.5rem 1rem;
color: var(--text-light);
font-size: 0.9rem;
text-align: center;
border-top: 1px solid var(--border);
}

h1 {
font-size: 3rem;
}
h2 {
font-size: 2.6rem;
margin-top: 3rem;
}
h3 {
font-size: 2rem;
margin-top: 3rem;
}
h4 {
font-size: 1.44rem;
}
h5 {
font-size: 1.15rem;
}
h6 {
font-size: 0.96rem;
}

p, h1, h2, h3, h4, h5, h6 {
overflow-wrap: break-word;
}

h1,
h2,
h3 {
line-height: 1.1;
}

@media only screen and (max-width: 720px) {
h1 {
font-size: 2.5rem;
}
h2 {
font-size: 2.1rem;
}
h3 {
font-size: 1.75rem;
}
h4 {
font-size: 1.25rem;
}
}

a,
a:visited {
color: var(--accent);
}
a:hover {
text-decoration: none;
}
button,
.button,
a.button, 
input[type="submit"],
input[type="reset"],
input[type="button"],
label[type="button"] {
border: none;
border-radius: var(--standard-border-radius);
background-color: var(--accent);
font-size: 1rem;
color: var(--bg);
padding: 0.7rem 0.9rem;
margin: 0.5rem 0;
text-decoration: none;
font-family: inherit;
line-height: normal;
}
.button[aria-disabled="true"], input:disabled,
textarea:disabled,
select:disabled,
button[disabled] {
cursor: not-allowed;
background-color: var(--disabled);
color: var(--text-light)
}
input[type="range"] {
padding: 0;
}

abbr[title] {
cursor: help;
text-decoration-line: underline;
text-decoration-style: dotted;
}
button:enabled:hover,
.button:not([aria-disabled="true"]):hover,
input[type="submit"]:enabled:hover,
input[type="reset"]:enabled:hover,
input[type="button"]:enabled:hover,
label[type="button"]:hover {
filter: brightness(1.4);
cursor: pointer;
}
.button:focus-visible,
button:focus-visible:where(:enabled),
input:enabled:focus-visible:where(
[type="submit"],
[type="reset"],
[type="button"]
) {
outline: 2px solid var(--accent);
outline-offset: 1px;
}

header > nav {
font-size: 1rem;
line-height: 2;
padding: 1rem 0 0 0;
}

header > nav ul,
header > nav ol {
align-content: space-around;
align-items: center;
display: flex;
flex-direction: row;
flex-wrap: wrap;
justify-content: center;
list-style-type: none;
margin: 0;
padding: 0;
}

header > nav ul li,
header > nav ol li {
display: inline-block;
}
header > nav a,
header > nav a:visited {
margin: 0 0.5rem 1rem 0.5rem;
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
color: var(--text);
display: inline-block;
padding: 0.1rem 1rem;
text-decoration: none;
}
header > nav a:hover,
header > nav a.current,
header > nav a[aria-current="page"] {
border-color: var(--accent);
color: var(--accent);
cursor: pointer;
}

@media only screen and (max-width: 720px) {
header > nav a {
border: none;
padding: 0;
text-decoration: underline;
line-height: 1;
}
}

aside, details, pre, progress {
background-color: var(--accent-bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
aside {
font-size: 1rem;
width: 30%;
padding: 0 15px;
margin-inline-start: 15px;
float: right;
}
*[dir="rtl"] aside {
float: left;
}

@media only screen and (max-width: 720px) {
aside {
width: 100%;
float: none;
margin-inline-start: 0;
}
}
article, fieldset, dialog {
border: 1px solid var(--border);
padding: 1rem;
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
article h2:first-child,
section h2:first-child {
margin-top: 1rem;
}
section {
border-top: 1px solid var(--border);
border-bottom: 1px solid var(--border);
padding: 2rem 1rem;
margin: 3rem 0;
}

section + section,
section:first-child {
border-top: 0;
padding-top: 0;
}
section:last-child {
border-bottom: 0;
padding-bottom: 0;
}
details {
padding: 0.7rem 1rem;
}
summary {
cursor: pointer;
font-weight: bold;
padding: 0.7rem 1rem;
margin: -0.7rem -1rem;
word-break: break-all;
}
details[open] > summary + * {
margin-top: 0;
}
details[open] > summary {
margin-bottom: 0.5rem;
}
details[open] > :last-child {
margin-bottom: 0;
}

table {
border-collapse: collapse;
margin: 1.5rem 0;
}
td,
th {
border: 1px solid var(--border);
text-align: start;
padding: 0.5rem;
}
th {
background-color: var(--accent-bg);
font-weight: bold;
}
tr:nth-child(even) {

background-color: var(--accent-bg);
}
table caption {
font-weight: bold;
margin-bottom: 0.5rem;
}

textarea,
select,
input {
font-size: inherit;
font-family: inherit;
padding: 0.5rem;
margin-bottom: 0.5rem;
color: var(--text);
background-color: var(--bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
box-shadow: none;
max-width: 100%;
display: inline-block;
}
label {
display: block;
}
textarea:not([cols]) {
width: 100%;
}

select:not([multiple]) {
background-image: linear-gradient(45deg, transparent 49%, var(--text) 51%),
linear-gradient(135deg, var(--text) 51%, transparent 49%);
background-position: calc(100% - 15px), calc(100% - 10px);
background-size: 5px 5px, 5px 5px;
background-repeat: no-repeat;
padding-inline-end: 25px;
}
*[dir="rtl"] select:not([multiple]) {
background-position: 10px, 15px;
}

input[type="checkbox"],
input[type="radio"] {
vertical-align: middle;
position: relative;
width: min-content;
}
input[type="checkbox"] + label,
input[type="radio"] + label {
display: inline-block;
}
input[type="radio"] {
border-radius: 100%;
}
input[type="checkbox"]:checked,
input[type="radio"]:checked {
background-color: var(--accent);
}
input[type="checkbox"]:checked::after {

content: " ";
width: 0.18em;
height: 0.32em;
border-radius: 0;
position: absolute;
top: 0.05em;
left: 0.17em;
background-color: transparent;
border-right: solid var(--bg) 0.08em;
border-bottom: solid var(--bg) 0.08em;
font-size: 1.8em;
transform: rotate(45deg);
}
input[type="radio"]:checked::after {

content: " ";
width: 0.25em;
height: 0.25em;
border-radius: 100%;
position: absolute;
top: 0.125em;
background-color: var(--bg);
left: 0.125em;
font-size: 32px;
}

@media only screen and (max-width: 720px) {
textarea,
select,
input {
width: 100%;
}
}

input[type="color"] {
height: 2.5rem;
padding: 0.2rem;
}

input[type="file"] {
border: 0;
}

hr {
border: none;
height: 1px;
background: var(--border);
margin: 1rem auto;
}
mark {
padding: 2px 5px;
border-radius: var(--standard-border-radius);
background-color: var(--marked);
color: black;
}
img,
video {
max-width: 100%;
height: auto;
border-radius: var(--standard-border-radius);
}
figure {
margin: 0;
display: block;
overflow-x: auto;
}
figcaption {
text-align: center;
font-size: 0.9rem;
color: var(--text-light);
margin-bottom: 1rem;
}
blockquote {
margin-inline-start: 2rem;
margin-inline-end: 0;
margin-block: 2rem;
padding: 0.4rem 0.8rem;
border-inline-start: 0.35rem solid var(--accent);
color: var(--text-light);
font-style: italic;
}
cite {
font-size: 0.9rem;
color: var(--text-light);
font-style: normal;
}
dt {
color: var(--text-light);
}

code,
pre,
pre span,
kbd,
samp {
font-family: var(--mono-font);
color: var(--code);
}
kbd {
color: var(--preformatted);
border: 1px solid var(--preformatted);
border-bottom: 3px solid var(--preformatted);
border-radius: var(--standard-border-radius);
padding: 0.1rem 0.4rem;
}
pre {
padding: 1rem 1.4rem;
max-width: 100%;
overflow: auto;
color: var(--preformatted);
}

pre code {
color: var(--preformatted);
background: none;
margin: 0;
padding: 0;
}



progress {
width: 100%;
}
progress:indeterminate {
background-color: var(--accent-bg);
}
progress::-webkit-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent-bg);
}
progress::-webkit-progress-value {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
}
progress::-moz-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
transition-property: width;
transition-duration: 0.3s;
}
progress:indeterminate::-moz-progress-bar {
background-color: var(--accent-bg);
}
dialog {
max-width: 40rem;
margin: auto;
}
dialog::backdrop {
background-color: var(--bg);
opacity: 0.8;
}
@media only screen and (max-width: 720px) {
dialog {
max-width: 100%;
margin: auto 1em;
}
}

.notice {
background: var(--accent-bg);
border: 2px solid var(--border);
border-radius: 5px;
padding: 1.5rem;
margin: 2rem 0;
}

strong{
color:#d81b60;
}
em {
color:#e0467e; 
}
hr
{
border: 1px;
clear: both;
display: block;
width: 100%;
height: 1px;

background-color:#686868
}
</style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Your Digest for Sunday, Feb 04, 2024 08:59 PM</h1>
</header>
<hr />
<p>Lung cancer is the leading cause if cancer death worldwide.</p>
<p><strong>Small cell lung cancer</strong>:<br />
Typical patient is a male older than 70, current or previous smoker.<br />
SCLC is defined by light microscopy as &quot;tumour with cells which uave a dmall size , scant cytoplasmic, absent of inconspicuous nucleoli&quot;.<br />
90% express TTF-1 which ?can be used for identification.<br />
Caused by mutations in TP53 and RB1 genes.</p>
<p>Occur in central airways causing <strong>symptoms within weeks</strong>.<br />
Commonly associated eith paraneoplastic syndromes.</p>
<ol>
<li>SIADH - 15 - 40%</li>
<li>Ectopic cushings 5%</li>
<li>Lambert eaton syndrome - 3%<br />
I&#39;m&gt;[!INFO] Definition of Paraneoplastic syndromes</li>
</ol>
<ul>
<li><em>Lung cancer</em> is the most common cancer associated <em>with neurologic syndromes</em>.</li>
<li>Mainly associated with <strong>Small Cell Lung Cancer (SCLC)</strong>.</li>
<li>Immune mediated.
<ol>
<li>Paraneoplastic LEMS is <strong>invariably</strong> associated with SCLC.</li>
</ol></li>
</ul>
<hr />
<pre><code>1. &gt;[!INFO] A for alternative
2. &gt;[!TIP] IgM and IgG activate the classical pathway but IgA based complexes appear to activate the alternate pathway as described above.
</code></pre>
<hr />
<h3 id="pathogenesis">pathogenesis</h3>
<p>The clinical syndrome of MG can w caused by various types of antibodies which block transmission at the <em><strong>neuromuscular</strong> junction</em>.</p>
<ul>
<li><p><strong>AChR</strong> - anti acetylcholine receptor antibodies</p>
<ul>
<li>are IgG which damage the postsynaptic membrane and its receptors (via complementary mediated mechanisms)</li>
</ul></li>
<li><p><strong>anti Muscle specific kinase</strong> (anti musk) - antibodies agains the musk proteins ehich is rewuired for proper clustering of post synaptic acetyl choline receptors.</p>
<ul>
<li>MuSK - less commonly found. (Muscle specific kinase antibody)</li>
<li></li>
</ul></li>
</ul>
<p>|Ocular and bulbar weakness<br />
predominant | proximal muscle weakness|</p>
<hr />
<h1 id="goodpastures-syndrome">Goodpasture&#39;s syndrome.</h1>
<table>
<thead>
<tr class="header">
<th>IgA <em>nephropathy</em></th>
<th>Henoch-Schonlein (IgA <em>vasculitis</em>)</th>
<th>Goodpasture Xn</th>
<th>ANCA positive vasculitis</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Young people</td>
<td>Children<br>rare over age &gt; 20;</td>
<td>30 and 50 year peaks</td>
<td>Older patients</td>
</tr>
<tr class="even">
<td>IgA based immune complex mediated nephropathy</td>
<td>Primary (IgA) Immune complex mediated Small vessel vasculitis</td>
<td>Primary Immune complex mediated Small vessel vasculitis</td>
<td>Pauci immune vaculitis</td>
</tr>
<tr class="odd">
<td>No pulmonary haemorrhage</td>
<td>Diffuse alveolar haemorrhage rare; commoner if HSP occursin adults / adolescents</td>
<td>Diffuse alveolar haemorrhage +</td>
<td>Life threatening alveolar haemorrhage</td>
</tr>
<tr class="even">
<td>-</td>
<td>-</td>
<td>1. pulmonary h&#39;rage<br>2. RPGN</td>
<td>1. pulmonary h&#39;rage<br>2. RPGN</td>
</tr>
<tr class="odd">
<td>purpura -</td>
<td><strong>purpura +</strong></td>
<td>purpura -</td>
<td><strong>purpura of lower extremities</strong></td>
</tr>
<tr class="even">
<td>IgA deposition in mesangium; mesangial proliferation<br>Granular deposits</td>
<td>Identical to IgA nephropathy.<br>? most likely granular deposits</td>
<td><strong>Linear</strong> immune complex deposition in kidney;<br><strong>IgG</strong> mediated -&gt; complement activation -&gt; c5a mediated neutrophil damage.</td>
<td>Pauci immune</td>
</tr>
<tr class="odd">
<td>Recurrences common</td>
<td>upto 1/3 show recurrencs</td>
<td>Recurrences rare</td>
<td>maintenance therapy continued for 2 to 3 years.</td>
</tr>
<tr class="even">
<td>Respiratory symtoms due to URTI 1-2 day before</td>
<td></td>
<td>Respiratory symptoms due to alveolar haemorrhaging; may precede renal symptoms by months.</td>
<td>Otitis, bloody nasal discharge, crusting.</td>
</tr>
<tr class="odd">
<td>Mesangial proliferation</td>
<td>mesangial proliferation upto crescent formation.</td>
<td>RPGN - crescents</td>
<td>mild focal glomerulonephritis upto crescent formation</td>
</tr>
<tr class="even">
<td>40% develop CKD -&gt; slow to progress</td>
<td>Self limiting in children;<br>more severe clinical course in adults. <br></td>
<td>Will develop CKD if <em>delayed presentation / management</em></td>
<td></td>
</tr>
<tr class="odd">
<td>ACEi/ ARB and <em>immunosuppresion as last line</em></td>
<td>Supportive management +/- steroids</td>
<td>IvIG and Immunosuppresion</td>
<td>Immunosuppresion required for all; induction and maintenance phases.<br>maintenance therapy continued for 2 to 3 years.</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li>Immune complex mediated, small vessel vasculitis.</li>
<li>Prototype disease of &quot;<em>diffuse alveolar haemorrhage syndromes</em>&quot;.</li>
</ul>
<ul>
<li>Diffuse alveolar haemorrhage syndromes consist of a triad of <strong>haemoptysis, anaemia and diffuse pulmonary infiltrates</strong>.</li>
</ul>
<ul>
<li>Respiratory symptoms may precede glomerulonephritis by weeks to months.</li>
<li>Mild to life threatening haemopsytis.<br />
<strong>Treatment</strong>: remove the antibodies by plasmapheresis and prevent recurrence with immunosuppression (prednisilone / cyclophosphamide)<br />
<strong>Prognosis:</strong> <em>Recurrence is rare</em>; earlier diagnosis -&gt; less severe renal failure -&gt; recovery; late diagnosis or significant renal impairment at presentation -&gt; chronic kidney disease and dialysis requirement.</li>
</ul>
<hr />
<p>| Granuloma + (<em><strong>&quot;granulomatosis&quot;</strong></em>) | Granuloma (-) |<br />
| ENT symptoms commoner | ENT involvement less common |</p>
<h5 id="diagnosis">Diagnosis</h5>
<ul>
<li>ANCA positivity for the respective ANCA.</li>
<li>Renal biopsy is indicated:
<ul>
<li>Granulomas + in GPA, not in MPA.</li>
<li>mild focal segmenl glomerulonephritis up to diffuse necrotizng crescenase</li>
</ul></li>
</ul>
<h5 id="treatment-of-gpa-and-mpa">Treatment of GPA and MPA</h5>
<blockquote>
<p>Immunosuppressive therapy is warranted in almost all patients with active GPA or MPA</p>
</blockquote>
<p>Immunosuppressive therapy consists of induction phase and maintenance phase.</p>
</body>
</html>
